According to the disclosure of HKSE on September 12, AIM Vaccine has submitted its prospectus to the main board. Previously, AIM Vaccine has officially announced its big progress—its mRNA COVID-19 vaccine has completed low-dose and medium-dose enrollment of adults at the Phase I Clinical Research Laboratory of Shulan (Hangzhou) Hospital, and the preliminary results indicated safety and good tolerance after vaccination.